April 21, 2020: At StemBioSys, Inc. we are committed to providing research tools that facilitate and enhance in vitro research, tissue modeling, drug development and diagnostics.

During the COVID–19 pandemic (caused by the coronavirus SARS-CoV-2) we have been working with a reduced staff in our research laboratory and manufacturing facility to maintain our current research tool products inventory needed to meet our current customer’s needs. Additionally, we have been busy working with various researchers and partners on grant applications directed at the development of in vitro tissue models. We are proposing the use of our platform in vitro cell derived extracellular matrix technology for the development of lung models which could be used to test various drugs and other therapies for respiratory diseases such as COVID-19, influenza and complications including respiratory distress syndrome. StemBioSys’ President and CEO Bob Hutchens stated “It is exciting and rewarding to mobilize our staff and technology in these areas of critical need such as those currently manifested by the Corona virus. We will do everything possible to support research in this area while continuing to support or current customers.”

StemBioSys has exhibited the value of its in vitro cell derived extracellular matrix in the expansion and differentiation of several different types of stem cells. Recently SBS researchers in collaboration with researchers at the New Jersey Center for Biomaterials and Rutgers University published a manuscript in the journal Acta Biomaterialia describing the use of an in vitro derived articular cartilage extracellular matrix for the expansion of these difficult to grow cells (Click here). This work exhibits yet another tissue specific model system using the company’s core technology to enhance in vitro research. SBS also recently acquired a majority stake in CarTox, a start-up company out of the University of Michigan, to develop a model system for differentiating induced pluripotent stem cells into mature cardiomyocytes.

At StemBioSys we will continue to strive for developing more biologically relevant in vitro model systems that support the rapid and accurate testing of new drugs.